Agilent Technologies, Inc.

DB:AG8 Stock Report

Market Cap: €36.6b

Agilent Technologies Valuation

Is AG8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AG8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AG8 (€128.68) is trading below our estimate of fair value (€158.33)

Significantly Below Fair Value: AG8 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AG8?

Key metric: As AG8 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AG8. This is calculated by dividing AG8's market cap by their current earnings.
What is AG8's PE Ratio?
PE Ratio29.4x
EarningsUS$1.29b
Market CapUS$37.93b

Price to Earnings Ratio vs Peers

How does AG8's PE Ratio compare to its peers?

The above table shows the PE ratio for AG8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23x
1SXP SCHOTT Pharma KGaA
24.5x15.7%€3.7b
GXI Gerresheimer
20.4x21.8%€2.3b
MRK Merck KGaA
22.3x11.1%€60.1b
IQV IQVIA Holdings
24.7x13.5%US$34.7b
AG8 Agilent Technologies
29.4x8.2%€37.9b

Price-To-Earnings vs Peers: AG8 is expensive based on its Price-To-Earnings Ratio (29.4x) compared to the peer average (23.3x).

Price to Earnings Ratio vs Industry

How does AG8's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
AG8 29.4xIndustry Avg. 37.6xNo. of Companies4PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AG8 is good value based on its Price-To-Earnings Ratio (29.4x) compared to the European Life Sciences industry average (38.2x).

Price to Earnings Ratio vs Fair Ratio

What is AG8's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AG8 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.4x
Fair PE Ratio20.2x

Price-To-Earnings vs Fair Ratio: AG8 is expensive based on its Price-To-Earnings Ratio (29.4x) compared to the estimated Fair Price-To-Earnings Ratio (20.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AG8 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€128.68
€143.54
+11.5%
6.0%€159.21€130.26n/a17
Dec ’25€128.66
€141.88
+10.3%
6.0%€157.49€128.86n/a17
Nov ’25€119.26
€138.65
+16.3%
5.5%€152.39€124.69n/a17
Oct ’25€132.80
€133.79
+0.7%
6.6%€149.06€117.44n/a17
Sep ’25€128.34
€131.89
+2.8%
7.0%€147.53€116.23n/a17
Aug ’25€130.26
€129.73
-0.4%
6.6%€142.26€114.73n/a16
Jul ’25€118.48
€130.67
+10.3%
6.9%€144.83€116.80n/a16
Jun ’25€120.94
€130.08
+7.6%
7.2%€142.88€115.23n/a17
May ’25€129.80
€141.20
+8.8%
6.2%€154.18€121.47n/a18
Apr ’25€135.75
€135.46
-0.2%
7.5%€151.98€115.14n/a18
Mar ’25€126.80
€133.64
+5.4%
7.7%€152.26€115.35n/a17
Feb ’25€120.15
€128.88
+7.3%
8.1%€152.34€110.80n/a17
Jan ’25€125.65
€123.29
-1.9%
11.1%€150.32€91.10n/a18
Dec ’24€116.80
€122.03
+4.5%
10.2%€138.69€91.85€128.6617
Nov ’24€95.86
€129.06
+34.6%
11.4%€152.86€98.47€119.2617
Oct ’24€107.05
€132.25
+23.5%
10.3%€154.33€99.41€132.8017
Sep ’24€111.35
€130.48
+17.2%
9.3%€150.24€101.39€128.3417
Aug ’24€110.20
€130.22
+18.2%
9.1%€148.23€104.58€130.2617
Jul ’24€107.90
€132.71
+23.0%
7.6%€149.47€115.54€118.4817
Jun ’24€107.85
€137.82
+27.8%
7.9%€159.07€117.90€120.9417
May ’24€120.40
€147.86
+22.8%
7.3%€158.81€115.91€129.8017
Apr ’24€123.44
€152.99
+23.9%
7.0%€163.19€119.11€135.7516
Mar ’24€128.96
€152.99
+18.6%
7.0%€163.19€119.11€126.8016
Feb ’24€138.58
€150.57
+8.7%
6.8%€157.52€117.68€120.1516
Jan ’24€140.82
€150.98
+7.2%
6.9%€160.11€119.61€125.6516
Dec ’23€147.92
€151.23
+2.2%
6.9%€161.50€120.65€116.8016

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 22:10
End of Day Share Price 2024/12/19 00:00
Earnings2024/10/31
Annual Earnings2024/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Agilent Technologies, Inc. is covered by 43 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird
Ishan MajumdarBaptista Research